In this supplement to Federal Practitioner , Dr. Sachdev Thomas reviews safety and efficacy results from a clinical trial in intermediate and poor risk patients with advanced renal cell carcinoma (RCC), the most common type of kidney cancer in the United States.
- Inpatient and outpatient data from the Veterans Health Administration
- Efficacy results vs a standard of care treatment
- Highlights from a trial which studied the treatment in patients with advanced RCC who received a prior anti-angiogenic therapy
About the Author
Sachdev Thomas, MD
Assistant Clinical Professor, Health Sciences
University of California San Francisco, Fresno